ESSA Pharma (EPIX)

Overall impact
C (54)

Commentary

ESSA Pharma is an average overall performer. With a 'C' rating of 53.6 for overall impact (49th percentile compared to all companies), ESSA Pharma ranks 127th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 123 others, and ahead of Evolus, Mayne Pharma, Summit Therapeutics and 24 others. On top material causes for ESSA Pharma's industry (Pharmaceuticals & Biotech), ESSA Pharma performs well in Technology Innovation (88.5 score) and Disease Eradication (96.6) and performs poorly in Reduced Inequality (31.7 score), Sustainable Use of Water (29.5), Humane Treatment of Animals (36.7) and 7 other causes where it received a 'D' or 'F' score.
Impact
Cause EPIX
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2009
Employees
35
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Bc, Canada
Share classes
EPIX
Description
ESSA Pharma Inc. is a clinical stage pharmaceutical company that focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada.
Material causes
Ethos considers the following causes material for ESSA Pharma, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.